Efficacy and Safety of Ascites Treatment in Liver Cirrhosis

Cirrhosis is one of the major health problems worldwide; and ascites is often its first and foremost manifestation. Despite the advances in modern hepatology, the presence of ascites is associated with a poor prognosis and high mortality. The aim of the study was to analyse data on the efficacy and safety of ascites treatment options, taking into account the pathophysiology of the condition. The analysis of literature and international guidelines on ascites management showed that cirrhotic ascites is treated with medication or surgery that interfere with pathogenetic mechanisms underlying the condition. Treatment of uncomplicated ascites depends on the severity of clinical manifestations. Patients with grade 1 ascites do not require treatment. Therapy for grade 2–3 ascites is aimed at reducing sodium intake and promoting its excretion with diuretics. The effect of diuretics should be assessed by daily monitoring of body weight. Close monitoring of serum creatinine and electrolyte levels is necessary to avoid severe electrolyte imbalance and mitigate the risk of diuretic-associated acute kidney injury. Another medical option to increase diuresis is the use of vasoconstrictors. Large volume paracentesis is the treatment of choice for patients with grade 3 ascites and refractory ascites. The most dangerous complication of paracentesis is circulatory dysfunction, which is prevented by limiting the volume of fluid removed to 5–6 liters per procedure and using plasma substitutes. If paracentesis is ineffective, new minimally invasive methods of treatment should be considered: transjugular intrahepatic portosystemic shunting and automated low-flow ascitic fluid removal system. However, given the poor prognosis, all patients with refractory ascites should be considered candidates for liver transplantation, which is currently the only effective treatment. The efficacy and safety of therapy may be enhanced by a personalised approach to choosing the treatment for ascites in cirrhosis, as well as further investigation of means to mitigate adverse reactions to medication and minimally invasive surgery.

1. Ivashkin VT, Mayevskaya MV, Pavlov ChS, Fedosyina EA, Bessonova EN, Pirogova IYu, Garbuzenko DV. Treatment of liver cirrhosis complications: Clinical guidelines of the Russian Scientific Liver Society and Russian gastroenterological association. Rossiyskiy zhurnal gastroenterologii, gepatologii i koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2016;26(4):71–102 (In Russ.)

2. European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J Hepatol. 2010;53(3):397–417. https://doi.org/10.1016/j.jhep.2010.05.004

3. Dyadyk AI, Kugler TE, Malovichko IS, Yarovaya NF, Rakitskaya IV. Principles of diuretic therapy at liver cirrhosis. Rossiyskiy zhurnal gastroenterologii, gepatologii i koloproktologii = Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(5):48–56 (In Russ.)

4. Gordon FD. Ascites. Clin Liver Dis. 2012;16(2):285–99. https://doi.org/10.1016/j.cld.2012.03.004

5. Zhao R, Lu J, Shi Y, Zhao H, Xu K, Sheng J. Current management of refractory ascites in patients with cirrhosis. J Int Med Res. 2018;46(3):1138–45. https://doi.org/10.1177/0300060517735231

6. Pedersen JS, Bendtsen F, Møller S. Management of cirrhotic ascites. Ther Adv Chronic Dis. 2015;6(3):124– 37. https://doi.org/10.1177/2040622315580069

7. Reynolds TB. Ascites. Clin Liver Dis. 2000;4(1):151– 68. https://doi.org/10.1016/s1089-3261(05)70101-x

8. Hasan M, Akbar SMF, Al Mahtab M, Kumar PJ. Textbook of hepato-gastroenterology. 1st edition. New Delhi: Jaypee Brothers Medical Publishers; 2015.

9. Moore KP, Wong F, Gines P, Bernardi M, Ochs A, Salerno F, et al. The management of ascites in cirrhosis: report on the consensus conference of the International Ascites Club. Hepatology. 2003;38(1):258–66. https://doi.org/10.1053/jhep.2003.50315

10. Garbuzenko DV, Arefyev NO. Current approaches to the management of patients with cirrhotic ascites. World J Gastroenterol. 2019;25(28):3738–52. https://doi.org/10.3748/wjg.v25.i28.3738

11. Arroyo V, Fernandez J. Relationship between systemic hemodynamics, renal dysfunction, and fluid retention in cirrhosis. Clin Liver Dis (Hoboken). 2013;2(3):120–2.

12. Solà E, Ginès P. Renal and circulatory dysfunction in cirrhosis: current management and future perspectives. J Hepatol. 2010;53(6):1135–45.

13. Bernardi M, Domenicali M. The renin-angiotensin-aldosterone system in cirrhosis. In: Ginès P, Arroyo V, Rodés J, Schrier RW, eds. Ascites and renal dysfunction in liver disease: pathogenesis, diagnosis and treatment. Malden: Blackwell; 2005. P. 43–54.

14. Ginès P, Cárdenas A, Schrier RW. Liver disease and the kidney. In: Schrier RW, ed. Diseases of the kidney and urinary tract. Philadelphia: Lippincott Williams & Wilkins; 2007. P. 2179–2205.

15. Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol. 2007;46(5):935–46. https://doi.org/10.1016/j.jhep.2007.02.001

16. Bernardi M, Moreau R, Angeli P, Schnabl B, Arroyo V. Mechanisms of decompensation and organ failure in cirrhosis: From peripheral arterial vasodilation to systemic inflammation hypothesis. J Hepatol. 2015;63(5):1272–84. https://doi.org/10.1016/j.jhep.2015.07.004

17. Neong SF, Adebayo D, Wong F. An update on the pathogenesis and clinical management of cirrhosis with refractory ascites. Expert Rev Gastroenterol Hepatol. 2019;13(4):293–305. https://doi.org/10.1080/17474124.2018.1555469

18. Dirchwolf M, Podhorzer A, Marino M, Shulman C, Cartier M, Zunino M, et al. Immune dysfunction in cirrhosis: Distinct cytokines phenotypes according to cirrhosis severity. Cytokine. 2016;77:14–25. https://doi.org/10.1016/j.cyto.2015.10.006

19. Mandorfer M, Schwabl P, Paternostro R, Pomej K, Bauer D, Thaler J, et al. Von Willebrand factor indicates bacterial translocation, inflammation, and procoagulant imbalance and predicts complications independently of portal hypertension severity. Aliment Pharmacol Ther. 2018;47(7):980–8. https://doi.org/10.1111/apt.14522

20. Rimola A, García-Tsao G, Navasa M, Piddock LJ, Planas R, Bernard B, Inadomi JM. Diagnosis, treatment and prophylaxis of spontaneous bacterial peritonitis: a consensus document. International Ascites Club. J Hepatol. 2000;32(1):142–53. https://doi.org/10.1016/s0168-8278(00)80201-9

21. Adebayo D, Neong SF, Wong F. Refractory ascites in liver cirrhosis. Am J Gastroenterol. 2019;114(1):40–7. https://doi.org/10.1038/s41395-018-0185-6

22. Wong F, Bendel E, Sniderman K, Frederick T, Haskal ZJ, Sanyal A, et al. Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump. Liver Transpl. 2020;26(5):651–61. https://doi.org/10.1002/lt.25724

23. Piano S, Tonon M, Angeli P. Management of ascites and hepatorenal syndrome. Hepatol Int. 2018;12(Suppl 1):122–34. https://doi.org/10.1007/s12072-017-9815-0

24. Biecker E. Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol. 2011;17(10):1237–48. https://doi.org/10.3748/wjg.v17.i10.1237

25. Aithal GP, Palaniyappan N, China L, Harmala S, Macken L, Ryan JM, et al. Guidelines on the management of ascites in cirrhosis. Gut. 2021;70(1):9–29. https://doi.org/10.1136/gutjnl-2020-321790

26. Tzamaloukas AH, Malhotra D, Rosen BH, Raj DSC, Murata GH, Shapiro JI. Principles of management of severe hyponatremia. J Am Heart Assoc. 2013;2(1):e005199. https://doi.org/10.1161/jaha.112.005199

27. Dyadyk AI, Taradin GG, Suliman YuV, Zborovskiy SR, Merkuriev VI. Diuretics in chronic kidney disease. Arkhiv vnutrenney meditsiny = Russian Archives of Internal Medicine. 2020;10(1):10–20 (In Russ.) https://doi.org/10.20514/2226-6704-2020-10-1-10-20

28. Kasztelan-Szczerbinska B, Cichoz-Lach H. Refractory ascites — the contemporary view on pathogenesis and therapy. Peer J. 2019;7:e7855. https://doi.org/10.7717/peerj.7855

29. Guo TT, Yang Y, Song Y, Ren Y, Liu ZX, Cheng G. Effects of midodrine in patients with ascites due to cirrhosis: Systematic review and meta-analysis. J Dig Dis. 2016; 17(1):11–9. https://doi.org/10.1111/1751-2980.12304

30. Hanafy AS, Hassaneen AM. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. Eur J Gastroenterol Hepatol. 2016;28(12):1455– 61. https://doi.org/10.1097/meg.0000000000000743

31. Lenaerts A, Codden T, Meunier JC, Henry JP, Ligny G. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system. Hepatology. 2006;44(4):844–9. https://doi.org/10.1002/hep.21355

32. Yang YY, Lin HC, Lee WP, Chu CJ, Lin MW, Lee FY, et al. Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial. Gut. 2010;59(11):1545–53. https://doi.org/10.1136/gut.2010.210732

33. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018;69(2):406–60. https://doi.org/10.1016/j.jhep.2018.03.024

34. Zhou X, Tripathi D, Song T, Shao L, Han B, Zhu J, et al. Terlipressin for the treatment of acute variceal bleeding: a systematic review and meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97(48):e13437. https://doi.org/10.1097/md.0000000000013437

35. Colle I, Laterre PF. Hepatorenal syndrome: the clinical impact of vasoactive therapy. Expert Rev Gastroenterol Hepatol. 2018;12(2):173–88. https://doi.org/10.1080/17474124.2018.1417034

36. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver. 2000;20(1):51–9. https://doi.org/10.1034/j.1600-0676.2000.020001051.x

37. Krag A, Møller S, Henriksen JH, Holstein-Rathlou NH, Larsen FS, Bendtsen F. Terlipressin improves renal function in patients with cirrhosis and ascites without hepatorenal syndrome. Hepatology. 2007;46(6):1863– 71. https://doi.org/10.1002/hep.21901

38. Kalambokis G, Economou M, Fotopoulos A, Bokharhii JA, Katsaraki A, Tsianos EV. Renal effects of treatment with diuretics, octreotide or both, in non-azotemic cirrhotic patients with ascites. Nephrol Dial Transplant. 2005;20(8):1623–9. https://doi.org/10.1093/ndt/gfh871

39. Zhang X, Wang SZ, Zheng JF, Zhao WM, Li P, Fan CL, et al. Clinical efficacy of tolvaptan for treatment of refractory ascites in liver cirrhosis patients. World J Gastroenterol. 2014;20(32):11400–5. https://doi.org/10.3748/wjg.v20.i32.11400

40. Bellos I, Kontzoglou K, Psyrri A, Pergialiotis V. Tolvaptan response improves overall survival in patients with refractory ascites: a meta-analysis. Dig Dis. 2020;38(4):320–8. https://doi.org/10.1159/000503559

41. Rodrigues SG, Mendoza YP, Bosch J. Beta-blockers in cirrhosis: evidence-based indications and limitations. JHEP Rep. 2019;2(1):100063. https://doi.org/10.1016/j.jhepr.2019.12.001

42. Krag A, Wiest R, Albillos A, Gluud LL. The window hypothesis: haemodynamic and non-haemodynamic effects of β-blockers improve survival of patients with cirrhosis during a window in the disease. Gut. 2012;61(7):967–9. https://doi.org/10.1136/gutjnl-2011-301348

43. Brito-Azevedo A. Diuretic window hypothesis in cirrhosis: Changing the point of view. World J Gastroenterol. 2019;25(26):3283–90. https://doi.org/10.3748/wjg.v25.i26.3283

44. Chirapongsathorn S, Valentin N, Alahdab F, Krittanawong C, Erwin PJ, Murad MH, Kamath PS. Nonselective β-blockers and survival in patients with cirrhosis and ascites: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016;14(8):1096–104.e9. https://doi.org/10.1016/j.cgh.2016.01.012

45. De Gottardi A, Thévenot T, Spahr L, Morard I, Bresson-Hadni S, Torres F, et al. Risk of complications after abdominal paracentesis in cirrhotic patients: a prospective study. Clin Gastroenterol Hepatol. 2009;7(8):906–9. https://doi.org/10.1016/j.cgh.2009.05.004

46. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol. 2002;37(4):463–70. https://doi.org/10.1016/s0168-8278(02)00208-8

47. Hung A, Garcia-Tsao G. Acute kidney injury, but not sepsis, is associated with higher procedure-related bleeding in patients with decompensated cirrhosis. Liver Int. 2018;38(8):1437–41. https://doi.org/10.1111/liv.13712

48. Kim JH. What we know about paracentesis induced circulatory dysfunction? Clin Mol Hepatol. 2015;21(4):349– 51. https://doi.org/10.3350/cmh.2015.21.4.349

49. Bernardi M, Caraceni P, Navickis RJ, Wilkes MM. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology. 2012;55(4):1172–81. https://doi.org/10.1002/hep.24786

50. Bernardi M, Caraceni P, Navickis RJ. Does the evidence support a survival benefit of albumin infusion in patients with cirrhosis undergoing large-volume paracentesis? Expert Rev Gastroenterol Hepatol. 2017;11(3):191–2. https://doi.org/10.1080/17474124.2017.1275961

51. Di Pascoli M, Fasolato S, Piano S, Bolognesi M, Angeli P. Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites. Liver Int. 2019;39(1):98–105. https://doi.org/10.1111/liv.13968

52. Kozaki K, IInuma M, Takagi T, Fukuda T, Sanpei T, Terunuma Y, et al. Cell-free and concentrated as cites reinfusion therapy for decompensated liver cirrhosis. Ther Apher Dial. 2016;20(4):376–82. https://doi.org/10.1111/1744-9987.12469

53. Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014;20(10):2704–14. https://doi.org/10.3748/wjg.v20.i10.2704

54. Allegretti AS, Ortiz G, Cui J, Wenger J, Bhan I, Chung RT, et al. Changes in kidney function after transjugular intrahepatic portosystemic shunts versus large-volume paracentesis in cirrhosis: a matched cohort analysis. Am J Kidney Dis. 2016;68(3):381–91. https://doi.org/10.1053/j.ajkd.2016.02.041

55. Bercu ZL, Fischman AM, Kim E, Nowakowski FS, Patel RS, Schiano TD, et al. TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stentgrafts. AJR Am J Roentgenol. 2015;204(3):654–61. https://doi.org/10.2214/ajr.14.12885

56. Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology. 2017;152(1):157– 63. https://doi.org/10.1053/j.gastro.2016.09.016

57. Miraglia R, Maruzzelli L, Tuzzolino F, Petridis I, D’Amico M, Luca A. Transjugular intrahepatic portosystemic shunts in patients with cirrhosis with refractory ascites: comparison of clinical outcomes by using 8- and 10-mm PTFEcovered stents. Radiology. 2017;284(1):281–8. https://doi.org/10.1148/radiol.2017161644

58. Rudler M, Mallet M, Sultanik P, Bouzbib C, Thabut D. Optimal management of ascites. Liver Int. 2020; 40(Suppl 1):128–35. https://doi.org/10.1111/liv.14361

59. Sarwar A, Zhou L, Novack V, Tapper EB, Curry M, Malik R, Ahmed M. Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States. Hepatology. 2018;67(2):690–9. https://doi.org/10.1002/hep.29354

60. Bellot P, Welker MW, Soriano G, von Schaewen M, Appenrodt B, Wiest R, et al. Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study. J Hepatol. 2013;58(5):922–7. https://doi.org/10.1016/j.jhep.2012.12.020

61. Stirnimann G, Berg T, Spahr L, Zeuzem S, McPherson S, Lammert F, et al. Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis. Aliment Pharmacol Ther. 2017;46(10):981–91. https://doi.org/10.1111/apt.14331

62. Bureau C, Adebayo D, Chalret de Rieu M, Elkrief L, Valla D, Peck-Radosavljevic M, et al. Alfapump® system vs. large volume paracentesis for refractory ascites: A multicenter randomized controlled study. J Hepatol. 2017;67(5):940–9. https://doi.org/10.1016/j.jhep.2017.06.010

63. Lepida A, Marot A, Trépo E, Degre D, Moreno C, Deltenre P. Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites. Aliment Pharmacol Ther. 2019;50(9):978–87. https://doi.org/10.1111/apt.15502

64. Wong F, Bendel E, Sniderman K, Frederick T, Haskal ZJ, Sanyal A, et al. Improvement in quality of life and de crease in large-volume paracentesis requirements with the automated low-flow ascites pump. Liver Transpl. 2020;26(5):651–61. https://doi.org/10.1002/lt.25724

65. Senousy BE, Draganov PV. Evaluation and management of patients with refractory ascites. World J Gastroenterol. 2009;15(1):67–80. https://doi.org/10.3748/wjg.15.67